Cytek Biosciences — Third Quarter 2026 Earnings Summary

Cytek Biosciences reported third-quarter 2026 total revenue of $53.2 million, a 2% increase from the prior year, driven by growth in the U.S. market and strong demand for high-end instruments. The company achieved a GAAP gross margin of 59%, representing a 590 basis point improvement, while expanding its installed base of instruments to 4,073 units. Operating expenses rose to $39.6 million, resulting in a net loss of $6.1 million for the quarter, though Adjusted EBITDA turned positive at $0.7 million. Cytek maintained its full-year 2026 revenue guidance midpoint at $208 million to $211 million and noted a recent legal victory in a patent infringement case in Delaware.